Tremfya
Total Payments
$12.1M
Transactions
49,030
Doctors
5,713
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $3.8M | 19,950 | 4,116 |
| 2018 | $8.3M | 24,159 | 4,061 |
| 2017 | $98,823 | 4,921 | 1,875 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.6M | 2,161 | 37.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.0M | 1,518 | 33.3% |
| Consulting Fee | $1.6M | 428 | 12.9% |
| Travel and Lodging | $884,558 | 1,464 | 7.3% |
| Food and Beverage | $845,317 | 41,167 | 7.0% |
| Education | $199,432 | 2,287 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $7,100 | 5 | 0.1% |
Payments by Type
General
$7.5M
46,869 transactions
Research
$4.6M
2,161 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis | Janssen Research & Development, LLC | $1.9M | 1 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Re | Janssen Research & Development, LLC | $773,050 | 2 |
| Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis | Janssen Research & Development, LLC | $663,948 | 1 |
| A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | Janssen Research & Development, LLC | $536,723 | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF A | Janssen Research & Development, LLC | $336,628 | 0 |
| A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa | Janssen Research & Development, LLC | $172,907 | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis | Janssen Research & Development, LLC | $135,337 | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered Via a SelfDose (TM) Device in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis | Janssen Research & Development, LLC | $44,965 | 1 |
| A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (=6 To | Janssen Research & Development, LLC | $25,500 | 1 |
| A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | Janssen Research & Development, LLC | $23,200 | 0 |
| A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis | Janssen Research & Development, LLC | $17,111 | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab | Janssen Research & Development, LLC | $7,380 | 0 |
| An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers | Janssen Research & Development, LLC | $5,143 | 0 |
| A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis | Janssen Research & Development, LLC | $1,000 | 0 |
Top Doctors Receiving Payments for Tremfya
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $4.4M | 2,135 |
| , MD | Dermatology | Winston Salem, NC | $247,848 | 156 |
| , MD | Dermatology | Macon, GA | $210,786 | 185 |
| , M.D | Dermatology | Sioux Falls, SD | $197,418 | 159 |
| , MD | Dermatology | Pittsburgh, PA | $194,378 | 140 |
| , MD | Dermatology | Rolling Meadows, IL | $191,582 | 36 |
| , MD | Procedural Dermatology | Tamarac, FL | $182,326 | 261 |
| , M.D., PH.D | Dermatology | New Haven, CT | $179,754 | 132 |
| , MD | Dermatology | Philadelphia, PA | $164,428 | 170 |
| , M.D | MOHS-Micrographic Surgery | Bakersfield, CA | $150,432 | 172 |
| , M.D | Dermatology | Exton, PA | $145,440 | 134 |
| , M.D., PHD | Dermatology | Santa Monica, CA | $143,118 | 157 |
| , M.D., PH.D | Dermatology | Bridgeport, CT | $121,841 | 104 |
| , M.D | Dermatology | Greenville, SC | $120,965 | 114 |
| , M.D | Dermatology | Encinitas, CA | $109,199 | 87 |
| , MD | Dermatology | Austin, TX | $99,519 | 86 |
| , D.O | Family Medicine | Stuart, FL | $92,561 | 80 |
| , MD | Dermatology | Dallas, TX | $90,152 | 88 |
| , M.D | Dermatology | Santa Ana, CA | $87,750 | 91 |
| , MD | Dermatology | East Windsor, NJ | $87,283 | 105 |
| , M.D | Specialist | Redding, CA | $81,127 | 108 |
| , M.D | Specialist | N Bethesda, MD | $80,683 | 72 |
| , MD | Dermatology | Portland, OR | $78,731 | 61 |
| , M.D | Diagnostic Radiology | Tacoma, WA | $74,377 | 6 |
| , MD | Dermatology | Miami, FL | $74,340 | 74 |
Ad
Manufacturing Companies
- Janssen Scientific Affairs, LLC $5.1M
- Janssen Research & Development, LLC $4.8M
- Janssen Biotech, Inc. $2.1M
- Janssen Global Services, LLC $167,145
- Janssen Pharmaceuticals, Inc $30,465
- Johnson & Johnson Health Care Systems Inc. $5,130
- Biosense Webster, Inc. $23.13
Product Information
- Type Drug
- Total Payments $12.1M
- Total Doctors 5,713
- Transactions 49,030
About Tremfya
Tremfya is a drug associated with $12.1M in payments to 5,713 healthcare providers, recorded across 49,030 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Scientific Affairs, LLC.
Payment data is available from 2017 to 2019. In 2019, $3.8M was paid across 19,950 transactions to 4,116 doctors.
The most common payment nature for Tremfya is "Unspecified" ($4.6M, 37.9% of total).
Tremfya is associated with 14 research studies, including "A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis" ($1.9M).